球囊扩张咽鼓管成形术联合鼓膜置管术治疗分泌性中耳炎的长期疗效与安全性:前瞻性随机对照试验研究方案
本研究为前瞻性、平行组、单盲随机对照试验,计划纳入124例分泌性中耳炎患者,随机分为单纯鼓膜置管组(A组)与鼓膜置管联合球囊扩张咽鼓管成形术组(B组)。主要结局为咽鼓管功能(ETDQ-7问卷和咽鼓管评分),次要结局包括中耳功能、听力和生活质量,随访至术后24个月。该研究旨在验证联合治疗对分泌性中耳炎的长期疗效与安全性,并探索其根治潜力。
要点
- 计划纳入124例分泌性中耳炎患者,随机分为单纯鼓膜置管组与联合球囊扩张咽鼓管成形术组。
- 主要结局为咽鼓管功能,采用ETDQ-7问卷和咽鼓管评分评估,随访至术后24个月。
- 该研究为在中国人群中首次开展的前瞻性试验,旨在验证联合治疗的长期疗效与安全性。
核心结论
- 该研究旨在验证球囊扩张咽鼓管成形术联合鼓膜置管术治疗分泌性中耳炎的长期疗效与安全性,并探索其根治潜力。
- 作者认为该试验的严谨设计可提高结果的可靠性,未来研究团队将进一步拓展联合治疗的临床证据与应用。
研究设计与样本
- 前瞻性、平行组、单盲、随机对照试验,计划纳入124例分泌性中耳炎患者,随机分为A组(常规鼓膜置管术)和B组(鼓膜置管术联合球囊扩张咽鼓管成形术)。
- 结局评估在基线及术后第3、6、12、24个月进行。
- 主要分析采用混合效应模型重复测量方差分析。
- 试验注册于中国临床试验注册中心,注册号ChiCTR2400079632,注册日期2024年1月8日。
关键数值与推荐
- 主要结局为咽鼓管功能,采用咽鼓管功能障碍问卷(ETDQ-7)和咽鼓管评分(ETS)测量。
- 次要结局包括中耳功能、听力和生活质量,分别采用声阻抗测量、纯音测听和中文版慢性耳病调查(CCES)评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Otitis media with effusion (OME) is a common disease in ear, nose, and throat clinics characterized by aural fullness and hearing loss and mainly caused by eustachian tube dysfunction (ETD). Tympanostomy tube insertion (TTI) is a conventional surgical treatment option that can alleviate symptoms but does not provide a definitive cure, and it is prone to recurrence. Balloon dilation eustachian tuboplasty (BDET) has become a novel procedure for the treatment of ETD, demonstrating significant potential in addressing the aforementioned limitations. However, it is not widely available in the clinic and few high-quality randomized clinical trials was conducted to investigate its long-term efficacy and security in OME. Therefore, the purpose of this study is to verify the efficacy of BDET combined with TTI for patients with OME and its prospects for providing a definitive cure. METHODS AND ANALYSIS: This is a prospective, parallel-group, single-blind, randomized controlled prospective trial. Totally 124 patients with OME will be randomized into either group A or B. Group A will receive conventional therapy (TTI) while group B will use BDET therapy in addition to TTI. Outcome assessments will take place at baseline and at the 3rd, 6th, 12th, and 24th months after surgery. The primary outcome is eustachian tube function, which will be measured by the eustachian tube dysfunction questionnaire (ETDQ-7) and eustachian tube score (ETS). The secondary outcomes include middle ear function, hearing situation, and quality of life, which will be measured by acoustic impedance measurement, pure-tone audiometry, and Chinese-version Chronic Ear Survey (CCES). The main analysis of change in the outcomes will use mixed-model with repeated measures (MMRM) analyses of variance (ANOVAs). DISCUSSION: This is the first prospective trial in Chinese populations that aims to validate the long-term efficacy and safety of BDET-combined TTI therapy in patients with OME. This parallel-group, single-blind, randomized controlled trial may provide an opportunity to decrease the recurrence rate of OME and explore a definitive cure for patients with OME. This trial's rigorous design enhances the reliability of the findings, ensuring a robust answer to the research question. In the future, the research team will further expand upon the clinical evidence and applications of the BDET combined therapy. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2400079632. Registered on 8 January 2024, https://www.chictr.org.cn/bin/project/edit?pid=214452 .
引用
- Wu P, Cao X, Zhang R, et al. The long-term efficacy and safety of balloon dilation eustachian tuboplasty combined with tympanostomy tube insertion for patients with otitis media with effusion: study protocol for a prospective randomized controlled trial. Trials. 2024. PMID: 39210408. doi:10.1186/s13063-024-08405-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。